JJIJ
PRVB

Johnson & Johnson Innovation - JJDC’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Johnson & Johnson Innovation - JJDC’s Portfolio PRVB Stock Details PRVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-574,973
Closed -$7.38M – 16
2020
Q3 		$7.38M Sell
574,973
-550,000
-49% -$6.95M 1.48% 9
2020
Q2 		$15.9M Hold
1,124,973
– – 3.12% 7
2020
Q1 		$10.3M Hold
1,124,973
– – 5.63% 5
2019
Q4 		$16.8M Buy
+1,124,973
New +$10M 6.04% 4

Other funds holding PRVB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
DCM
DG Capital Management New York $326M AUM 39.67% 1-Year Est. Return

Johnson & Johnson Innovation - JJDC's PRVB Position: Q4 2020 in Review

Johnson & Johnson Innovation - JJDC sold out of Provention Bio, Inc. Common Stock (PRVB) in Q4 2020, closing a stake of 574,973 shares — an estimated $7.38M sold.

Johnson & Johnson Innovation - JJDC first reported a position in PRVB in Q4 2019 and held it in 4 quarters. The position peaked at $16.8M in Q4 2019. 106 funds tracked by Wall St. Rank hold PRVB as of Q4 2020.

  • Johnson & Johnson Innovation - JJDC reported no remaining Provention Bio, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Johnson & Johnson Innovation - JJDC sold 574,973 Provention Bio, Inc. Common Stock shares in Q4 2020, an estimated $7.38M.
  • Johnson & Johnson Innovation - JJDC first reported a position in Provention Bio, Inc. Common Stock in Q4 2019 and held it in 4 quarters.
  • Johnson & Johnson Innovation - JJDC's Provention Bio, Inc. Common Stock position peaked at $16.8M in Q4 2019.
  • 106 funds tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q4 2020.

Based on Johnson & Johnson Innovation - JJDC's 13F filing for Q4 2020, filed 9 Feb 2021.